New Releases from NCBI BookshelfEtranacogene Dezaparvovec (Hemgenix): CADTH Reimbursement Recommendation: Indication: For treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes [Internet].​Etranacogene Dezaparvovec (Hemgenix): CADTH Reimbursement Recommendation: Indication: For treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes [Internet].